Study: Biomarkers help predict MCI progression to Alzheimer's

03/21/2013 | MedPage Today (free registration)

Cerebrospinal fluid biomarkers, such as amyloid B-42, T-tau and P-tau, could help pinpoint patients with mild cognitive impairment who are likely to develop Alzheimer's disease, according to findings presented at a neurology meeting. Patients with MCI who progressed to Alzheimer's in three years had lower baseline levels of amyloid B-42 and higher baseline T-tau and P-tau compared with patients with stable cognitive impairment or other forms of dementia. Assessment of the biomarkers yielded 89% sensitivity, 77% specificity, 73% positive predictive value and 91% negative predictive value, said the study, which used MRI and PET scans as part of the methodology.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN